Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is on a path towards stabilization and improved profitability under the newly appointed leadership team, as demonstrated by their Q3 results with revenue growth and improved margins. Their focus on costs, margins, and operational discipline, along with a new credit facility, suggests a potential for sustainable profitability in the future. However, their future success will depend on their ability to increase treatment center utilization and patient conversion in the US without significantly expanding their sales force. Ultimately, Pulmonx has the potential for long-term growth in the minimally-invasive treatment market for severe emphysema patients.

Bears say

Pulmonx is facing numerous risks, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. These risks, along with declining sales in the US and high operating expenses, resulted in a net loss of $54.0M in 2025. Upcoming earnings will be an important indicator of the company's future performance.

Pulmonx (LUNG) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 6 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.